257
Participants
Start Date
November 24, 2009
Primary Completion Date
October 12, 2010
Study Completion Date
March 2, 2011
Pneumococcal vaccine GSK2189242A (formulation 1)
Three doses will be administered intramuscularly, at Month 0, 2 and 6.
Pneumococcal vaccine GSK2189242A (formulation 2)
Three doses will be administered intramuscularly, at Month 0, 2 and 6
Pneumococcal vaccine GSK2189242A combined with pneumococcal vaccine GSK1024850A (formulation 3)
Three doses will be administered intramuscularly, at Month 0, 2 and 6
Pneumococcal vaccine GSK2189242A combined with pneumococcal vaccine GSK1024850A (formulation 4)
Three doses will be administered intramuscularly, at Month 0, 2 and 6
Pneumococcal vaccine GSK1024850A
Three doses will be administered intramuscularly, at Month 0, 2 and 6
GSK Investigational Site, Prague
GSK Investigational Site, Odolena Voda
GSK Investigational Site, Chomutov
GSK Investigational Site, Ostrava - Poruba
GSK Investigational Site, Děčín
GSK Investigational Site, Náchod
GSK Investigational Site, Pardubice
GSK Investigational Site, Pilsen
GSK Investigational Site, Prague
GSK Investigational Site, Znojmo
Lead Sponsor
GlaxoSmithKline
INDUSTRY